Biggest Barriers to Market Access in the Evolving Healthcare Landscape

Pharmaceuticals and Biotech Market Access

June 18, 2024

As healthcare evolves, so does market access. From new team structures to mergers and acquisitions, pharma and device manufacturers must now navigate, adapt, and pivot within a new set of norms. To better understand the shifting landscape, we asked ADVI experts Yana Volman, solution leader, Market Access, Biopharma, and Josh Greenblatt, senior vice president, Market Access, and to provide a quick overview of some of the key issues that are shaping market access strategies today.

With the evolving healthcare landscape, one of the most critical actions for pharmaceutical and device manufacturers is to stay nimble and learn to pivot and adapt team structures to the set of customers, stakeholders, and decision-makers. With the emergence of new behaviors and challenges, optimizing engagement with organized customers has become imperative now more than ever. Teams must increase their relevance, deepen their understanding of customers’ business models and priorities, expand relationships within organizations to cross-business units, and look beyond the scope of their traditional engagement.

This becomes increasingly important with the rise in mergers and acquisitions where entities may now reach across provider practices, healthcare coverage, policy design, and beyond. While vertical and horizontal integration can potentially increase healthcare delivery efficiencies, it raises concerns about centralized decision-making and its impact on patient care. Increased industry consolidation may also increase barriers to effective conversations about appropriate access.

In addition to changing business models and increasing control, a rise in “me-too” competition and financial pressures has made market penetration more difficult. With eroding profitability and pressure from centralized distribution chains, devising effective contracting and channel strategies becomes paramount.

Finally, manufacturers need to keep an eye on the future to stay ahead of the curve and evolve in anticipation of future trends to mitigate barriers to access. They should continue to deepen their focus on field teams’ agility, budget impact modeling, channel optimization, and – ultimately – patient access.

Learn More

Stay ahead of the curve. Get in touch today for expert insights and strategic counsel on the evolving market access landscape.


CEO insights

Real analysis from people who’ve been there

ADVI Health Accelerates Insights with Monthly Medicare Data

ADVI Health now has access to 100% of Medicare Parts A, B, and D research files with monthly availability – …

August 12, 2026

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

Precision Medicine

FDA Proposes Down-Classification of Oncology Companion Diagnostics: A Q&A on Precision Medicine

The Food and Drug Administration (FDA) has announced a significant proposed change affecting oncology companion diagnostics (CDx) that could streamline …

December 16, 2025

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Inflation Reduction Act Pharmaceuticals and Biotech

Why is Medicare Data Central to IRA Negotiations?

The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …

September 10, 2025

Pharmaceuticals and Biotech

ADVI Analysis: MACPAC October 2024 Meeting

MACPAC held a meeting on October 31 and November 1, 2024 (link). The following relevant topics were discussed: ADVI Angle …

November 11, 2024

Inflation Reduction Act Pharmaceuticals and Biotech State Policy

ADVI Instant: CMS Releases 2026 Notice of Benefit and Payment Parameters Proposed Rule

On October 4, 2024, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule titled “HHS Notice of …

Brenna Raines, MHA
October 21, 2024

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.